Gene Therapy

OCU400, a gene therapy candidate, has received a second orphan drug designation from the FDA for the treatment of CEP290 mutation associated retinal disease, Ocugen announced in a press release.

Wize Pharma has entered into an exclusive license agreement to develop and commercialize products based on non-viral gene therapy technology from Copernicus Therapeutics, the company announced in a press release.

Here are some of the past week’s top stories on Healio.com/OSN:

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space.

NHS England will fund Luxturna gene therapy treatment for inherited retinal dystrophies starting in January 2020, according to a press release.

RGX-314, Regenxbio’s gene therapy using NAV vectors for AAV-mediated antibody delivery, has shown positive phase 1/2a results in patients with wet age-related macular degeneration, continuing to be well tolerated across five dose cohorts, according to a press release.

In this video, Clark Chang, OD, a part of the corneal team at Wills Eye Hospital in Philadelphia and director of Global Medical Affairs at Glaukos, speaks with Healio about treatment options for neurotrophic keratitis currently in the pipeline.